Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219128 · ClinicalTrials.gov registry record · Phase 3
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
NCT00219128: Completed Phase 3 study, sponsored by Novartis.
NCT00219128 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 671 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219128, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
Study Summary
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
What the finished NCT00219128 record still lists
NCT00219128 is an interventional study that assigns participants to a tested intervention. The registered 671 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00219128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219128 about?
NCT00219128 is a clinical study titled "A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.". Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
What is the current status of trial NCT00219128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2004-11. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00219128?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219128?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00219128's enrollment target sits among peer trials
671 544th of 2000 higher than 1,455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07184944 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07185009 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia